GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

The FINANCIAL — Merck on June 13 announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic insulin glargine candidate for the treatment of people with ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some ...

After nearly seven months and two prior recalls, Viatris continues to be vexed by labeling issues on its biosimilar to Sanofi’s diabetes blockbuster Lantus. Viatris’ Mylan this week said it was once ...

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

Credit: Getty Images. Insulin glargine 300 Units/mL was found to be comparable to insulin glargine 100 Units/mL in providing effective glycemic control in pediatric patients with type 1 diabetes.

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...

The European Medicines Agency (EMEA) is looking into four recently published registry studies investigating a possible relationship between insulin analogues, in particular insulin glargine, and the ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Civica will begin selling a type of insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s ...